CS

Carol Suh

Founder of Neumora

San Francisco Bay Area

Overview

Work Experience

  • Partner

    2021 - Current

    Board Member: Orbital Therapeutics, Human Immunology Biosciences (acquired) Board Observer: Kisbee Therapeutics (2021-Present), Remix Therapeutics (2021-Present), Resonance Medicine (2021-2023), Sesh Therapy (2021-2023), Locana Bio (2020-2024), CERo Therapeutics (2020-2022), Metacrine (2019-2020),

  • Principal

    2019 - 2021

  • Senior Associate

    2018 - 2019

  • Consultant/Intern

    2018 - 2018

  • Co-Founder and Chief Operating Officer

    2023

  • Co-Founder and SVP, Strategy

    2022 - 2023

  • Co-founder and VP, Business Development

    2019 - 2021

  • Co-founder, Board Member

    2022

  • Board Member

    2021

  • Board Member of Metrodora Foundation

    2021

  • Associate Director of Corporate Development

    2019 - 2019

    ARCH Venture Partners company build

  • Business Development and Corporate Strategy Associate; Launch Fellow

    2016 - 2017

    Business Development and Corporate Strategy Associate (Jun 2017-Sept 2017) Launch Fellow (May 2016-Aug 2016): Helped prepare Magenta Therapeutics for launch and $48.5M Series A, working with Third Rock Ventures and Atlas Venture.

  • Senior Associate Consultant

    2015 - 2016

    Senior Associate Consultant (2016) Associate Consultant (2015)

  • R&D Strategy; Innovation Fellow

    2014 - 2014

    The Regenerative Medicine Discovery Performance Unit built a portfolio of innovative stem cell and regenerative medicines through in-house R&D, strategic alliances, and in-licensing opportunities.

Relevant Websites